These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 8174200

  • 1. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
    Gandhi V, Robertson LE, Keating MJ, Plunkett W.
    Cancer Chemother Pharmacol; 1994; 34(1):30-6. PubMed ID: 8174200
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V, Kemena A, Keating MJ, Plunkett W.
    Cancer Res; 1992 Feb 15; 52(4):897-903. PubMed ID: 1737352
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V, Estey E, Keating MJ, Plunkett W.
    J Clin Oncol; 1993 Jan 15; 11(1):116-24. PubMed ID: 8418222
    [Abstract] [Full Text] [Related]

  • 4. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W.
    Clin Cancer Res; 1995 Feb 15; 1(2):169-78. PubMed ID: 9815970
    [Abstract] [Full Text] [Related]

  • 5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 15; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 6. Biochemical modulation of arabinosylcytosine for therapy of leukemias.
    Gandhi V, Estey E, Keating MJ, Plunkett W.
    Leuk Lymphoma; 1993 Sep 15; 10 Suppl():109-14. PubMed ID: 8481660
    [Abstract] [Full Text] [Related]

  • 7. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.
    Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322
    [Abstract] [Full Text] [Related]

  • 8. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
    Gandhi V, Nowak B, Keating MJ, Plunkett W.
    Blood; 1989 Nov 01; 74(6):2070-5. PubMed ID: 2478221
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK.
    Clin Cancer Res; 1998 Jan 01; 4(1):45-52. PubMed ID: 9516951
    [Abstract] [Full Text] [Related]

  • 10. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 01; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 11. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
    Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ.
    Leuk Lymphoma; 1993 Mar 01; 9(4-5):343-50. PubMed ID: 8394169
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy.
    Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W.
    Cancer Chemother Pharmacol; 1992 Mar 01; 31(3):193-9. PubMed ID: 1464155
    [Abstract] [Full Text] [Related]

  • 13. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 01; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

  • 14. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
    Gandhi V, Kemena A, Keating MJ, Plunkett W.
    Leuk Lymphoma; 1993 May 01; 10(1-2):49-56. PubMed ID: 8374523
    [Abstract] [Full Text] [Related]

  • 15. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
    Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W.
    Blood; 1996 Jan 01; 87(1):256-64. PubMed ID: 8547650
    [Abstract] [Full Text] [Related]

  • 16. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
    Gandhi V, Plunkett W.
    Cancer Chemother Pharmacol; 1992 Jan 01; 31(1):11-7. PubMed ID: 1458554
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
    Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ.
    J Clin Oncol; 2001 Apr 15; 19(8):2142-52. PubMed ID: 11304766
    [Abstract] [Full Text] [Related]

  • 18. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
    Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ.
    Leuk Lymphoma; 1999 Dec 15; 36(1-2):57-65. PubMed ID: 10613450
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S, Yamauchi T, Kawai Y, Takemura H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.
    Int J Hematol; 2007 Feb 15; 85(2):108-15. PubMed ID: 17321987
    [Abstract] [Full Text] [Related]

  • 20. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia.
    Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M.
    Cancer; 1993 Oct 01; 72(7):2155-60. PubMed ID: 8374873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.